openPR Logo
Press release

Peyronie’s Disease Treatment Market to Rear Excessive Growth With Key Players Endo International,Xiaflex,Xiapex

10-23-2018 04:04 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Peyronie?s Disease

Peyronie?s Disease

A penile prosthetic device is another good treatment option for Peyronie's disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque.

"With Xiaflex the only FDA approved product for this disease, Endo dominates the market"

The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product is estimated to generate USD 100 million in revenue for Peyronie’s disease by 2018. In Japan, BioSpecifics Technologies Corp. has granted Asahi Kasei Pharma the rights to develop and market XIAFLEX in Japan for Peyronie's disease. Further, the company is also partnering with global companies in Canada, Europe, Mexico, and Brazil for commercializing XIAFLEX for PD.

Get The Holistic SAMPLE Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/61

With increasing awareness and research on this disease, new drug molecules could be made available in the market.

The exact cause of plaque formation is not known. Hence, treatment is done with the available research and knowledge of plaque formation. There are various treatment options followed for Peyronie’ disease basis on which the market is analyzed. These include drugs, surgery and devices. The drugs market can be analyzed based on the administration route i.e. oral and injectable. On the other hand injectables show some positive outcomes over placebo. However, more studies are required to establish the efficacy. Studies with collagenase have shown positive outcomes for its use in Peyronie's disease.

Drugs prescribe through oral route include Vitamin E, Potassium amino-benzoate ("Potaba"), Tamoxifen, Colchicine, and Carnitine. Similarly, the injectable drugs include Verapamil, Interferon, and Collagenase. Use of oral drugs is limited as none of the studies conducted so far for Peyroniee’s disease have shown positive results of these drugs over the placebo. Therefore, Xiaflex (Collagenase clostridium histolyticum) from BioSpecifics Technologies Corporation is the only FDA approved product indicated for Peyronie's disease in adult men. Approved in 2013, Xiaflex is marketed in the U.S. by Endo International plc. In Europe, Collagenase clostridium histolyticum is available by the brand name Xiapex.

Peyronie’s disease is a rare condition observed in about 6 out of 100 men in the age group of 40 to 70 years. Moreover, the Urology Care Foundation also estimates that the number of people affected by this condition can be higher than this as many men are embarrassed and do not see their healthcare provider. It is mostly at times when the men visit the healthcare practitioner for erectile dysfunction treatment and the healthcare practitioner may notice Peyronie’s disease. Lack of awareness among patients has resulted in under reporting of this condition.

"With Xiaflex the only FDA approved product for this disease, Endo dominates the market"

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/61

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Peyronie’s Disease Treatment Market to Rear Excessive Growth With Key Players Endo International,Xiaflex,Xiapex here

News-ID: 1322630 • Views: 1547

More Releases from Coherent Market Insights

Explosive Detection Technologies Market 2022 Growth, Share, Strategies And Globa …
According to research published by CMI, the Explosive Detection Technologies Market is estimated to be worth US$ 11,445.2 Million by 2027, with a CAGR of 7.0 % over the forecast period (2019-2027). Explosive Detection Technologies Market 2022-2027 research report from Coherent Market Insights examines the market's flow state and key components to provide an in-depth look at the market. It accurately sends important data and cutting-edge analysis to help establish a
Zero Liquid Discharge Market 2022 Insights, Share, Trends With Global Opportunit …
According to research published by Coherent Market Insights, the Zero Liquid Discharge Market is estimated to be worth US$ 1,253.08 million by 2027, with a CAGR of 8.7% over the forecast period (2019-2027). The Zero Liquid Discharge 2022-2027 research report from Coherent Market Insights examines the market's flow state and key components to provide an in-depth look at the market. It accurately sends important data and cutting-edge analysis to help establish
Refrigerated Trailer Market 2022 - Industry Share, Challenges, Opportunities And …
According to the CMI report, The global refrigerated trailer market is predicted to reach US$ 1,801.00 Million in 2019 and grow at a CAGR of 5.4 % over the next five years. This in-depth analysis of the Refrigerated Trailer Market contains comprehensive market figures as well as information on the present state of the global and regional markets. Its comprehensive study covers everything from market circumstances to pricing comparisons among big corporations,
Photonic IC Market 2022: Development Trends And Global Opportunities Forecast to …
According to a report published by Coherent Market Insights, the Photonic IC Market is estimated to be worth US$ 17,075.6 million by 2027, with a CAGR of 42.6 % over the forecast period (2020-2027). This in-depth analysis of the Photonic IC Market contains comprehensive market figures as well as information on the present state of the global and regional markets. Its comprehensive study covers everything from market circumstances to pricing comparisons

All 5 Releases


More Releases for Peyronie

Peyronie’s Disease Treatment Market Set to Encounter Paramount Growth
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market Growing Popularity and Emerging Trend by 2026
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Treatment Market Is Likely to Witness Tremendous Growth by …
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
With Xiaflex the only FDA approved product for this disease, Endo dominates the …
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Treatment Market With Major Key Players Like BioSpecifics T …
The exact cause of plaque formation is not known. Hence, treatment is done with the available research and knowledge of plaque formation. There are various treatment options followed for Peyronie’ disease basis on which the market is analyzed. These include drugs, surgery and devices. The drugs market can be analyzed based on the administration route i.e. oral and injectable. Drugs prescribe through oral route include Vitamin E, Potassium amino-benzoate ("Potaba"),